Atrial natriuretic peptide and related peptides

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 10, 2007, Pages 1259-1267

  Akashi, Yoshihiro J ^a,b   Springer, Jochen ^a   Lainscak, Mitja ^c,d   Anker, Stefan D ^c,e  

^a DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d General Hospital Murska Sobota   (Slovenia)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Acute coronary syndrome; Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); C type natriuretic peptide (CNP); Dendroaspis natriuretic peptide (DNP); Heart failure; Renal failure

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DENDROASPIS NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; RECOMBINANT BRAIN NATRIURETIC PEPTIDE; RECOMBINANT HORMONE; UNCLASSIFIED DRUG; URODILATIN;

BIOLOGICAL MONITORING; BODY FLUID; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CLINICAL CHEMISTRY; DIAGNOSTIC APPROACH ROUTE; DRUG POTENCY; HEART FAILURE; HEMODYNAMIC PARAMETERS; HOMEOSTASIS; HUMAN; LUNG CAPILLARY PRESSURE; PATHOPHYSIOLOGY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW; SYSTEMIC VASCULAR RESISTANCE;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ELAPID VENOMS; HOMEOSTASIS; HUMANS; KIDNEY DISEASES; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; PEPTIDE FRAGMENTS; PEPTIDES;

DENDROASPIS;

EID: 35048813923     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.274     Document Type: Review

References (103)

1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.
2. Kangawa K, Fukuda A, Kubota I, Hayashi Y, Minamitake Y, Matsuo H. Human atrial natriuretic polypeptides (hANP): purification, structure synthesis and biological activity. J Hypertens Suppl 1984;2:S321-3.
3. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
4. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990;168:863-70.
5. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 1992;267:13928-32.
6. Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988;66:752-9.
7. Schirger JA, Heublein DM, Chen HH, Lisy O, Jougasaki M, Wennberg PW, et al. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc 1999;74:126-30.
8. Oikawa S, Imai M, Ueno A, Tanaka S, Noguchi T, Nakazato H, et al. Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide. Nature 1984;309:724-6.
9. Vuolteenaho O, Arjamaa O, Ling N. Atrial natriuretic polypeptides (ANP): rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. Biochem Biophys Res Commun 1985;129:82-8.
10. Gunning M, Brenner BM. Urodilatin: a potent natriuretic peptide of renal origin. Curr Opin Nephrol Hypertens 1993;2:857-62.
11. Forssmann WG, Meyer M, Schulz-Knappe P. Urodilatin: from cardiac hormones to clinical trials. Exp Nephrol 1994;2:318-23.
12. Porter JG, Arfsten A, Palisi T, Scarborough RM, Lewicki JA, Seilhamer JJ. Cloning of a cDNA encoding porcine brain natriuretic peptide. J Biol Chem 1989;264:6689-92.
13. Seilhamer JJ, Arfsten A, Miller JA, Lundquist P, Scarborough RM, Lewicki JA, et al. Human and canine gene homologs of porcine brain natriuretic peptide. Biochem Biophys Res Commun 1989;165:650-8.
14. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988-94.
15. Barr CS, Rhodes P, Struthers AD. C-type natriuretic peptide. Peptides 1996;17:1243-51.
16. Tawaragi Y, Fuchimura K, Tanaka S, Minamino N, Kangawa K, Matsuo H. Gene and precursor structures of human C-type natriuretic peptide. Biochem Biophys Res Commun 1991;175:645-51.
17. Stingo AJ, Clavell AL, Heublein DM, Wei CM, Pittelkow MR, Burnett JC Jr. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol 1992;263:H1318-21.
18. Togashi K, Kameya T, Kurosawa T, Hasegawa N, Kawakami M. Concentrations and molecular forms of C-type natriuretic peptide in brain and cerebrospinal fluid. Clin Chem 1992;38:2136-9.
19. Kuhn M. Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol 2004;99:76-82.
20. Singh G, Kuc RE, Maguire JJ, Fidock M, Davenport AP. Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure. Circ Res 2006;99:183-90.
21. Misono KS. Natriuretic peptide receptor: structure and signaling. Mol Cell Biochem 2002;230:49-60.
22. Pandey KN. Intracellular trafficking and metabolic turnover of ligand-bound guanylyl cyclase/atrial natriuretic peptide receptor-A into subcellular compartments. Mol Cell Biochem 2002;230:61-72.
23. Clerico A, Emdin M. Natriuretic peptides: the hormones of the heart. Milan: Springer, 2006:21-51.
24. Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000;167:239-46.
25. Andreassi MG, Del Ry S, Palmieri C, Clerico A, Biagini A, Giannessi D. Up-regulation of "clearance" receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur J Heart Fail 2001;3:407-14.
26. Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, et al. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol 2000;35:796-801.
27. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006;69:318-28.
28. Achilihu G, Frishman WH, Landau A. Neutral endopeptidase inhibitors and atrial natriuretic peptide. J Clin Pharmacol 1991;31:758-62.
29. Worthley MI, Corti R, Worthley SG. Vasopeptidase inhibitors: will they have a role in clinical practice? Br J Clin Pharmacol 2004;57:27-36.
30. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol 2003;285:F167-77.
31. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986;78:1362-74.
32. Fujio N, Ohashi M, Nawata H, Kato K, Ibayashi H, Kangawa K, et al. Alpha-human atrial natriuretic polypeptide reduces the plasma arginine vasopressin concentration in human subjects. Clin Endocrinol (Oxf) 1986;25:181-7.
33. Chu A, Morris KG, Kuehl WD, Cusma J, Navetta F, Cobb FR. Effects of atrial natriuretic peptide on the coronary arterial vasculature in humans. Circulation 1989;80:1627-35.
34. Cargill RI, Lipworth BJ. Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans. Thorax 1995;50:183-5.
35. Blackburn RE, Samson WK, Fulton RJ, Stricker EM, Verbalis JG. Central oxytocin and ANP receptors mediate osmotic inhibition of salt appetite in rats. Am J Physiol 1995;269:R245-51.
36. Zeidel ML. Regulation of collecting duct Naq reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995;22:121-4.
37. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
38. Walther T, Klostermann K, Heringer-Walther S, Schultheiss HP, Tschope C, Stepan H. Fibrosis rather than blood pressure determines cardiac BNP expression in mice. Regul Pept 2003;116:95-100.
39. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76:91-6.
40. Grantham JA, Borgeson DD, Burnett JC Jr. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol 1997;272:R1077-83.
41. McGrath MF, de Bold AJ. Determinants of natriuretic peptide gene expression. Peptides 2005;26:933-43.
42. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006;290:H17-29.
43. Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998;32(Suppl 3):S22-8.
44. Del Ry S, Passino C, Emdin M, Giannessi D. C-type natriuretic peptide and heart failure. Pharmacol Res 2006;54:326-33.
45. Furuya M, Miyazaki T, Honbou N, Kawashima K, Ohno T, Tanaka S, et al. C-type natriuretic peptide inhibits intimal thickening after vascular injury. Ann NY Acad Sci 1995;748:517-23.
46. Carvajal JA, Aguan K, Thompson LP, Buhimschi IA, Weiner CP. Natriuretic peptide-induced relaxation of myometrium from the pregnant guinea pig is not mediated by guanylate cyclase activation. J Pharmacol Exp Ther 2001;297:181-8.
47. El-Gehani F, Tena-Sempere M, Ruskoaho H, Huhtaniemi I. Natriuretic peptides stimulate steroidogenesis in the fetal rat testis. Biol Reprod 2001;65:595-600.
48. Walther T, Stepan H. C-type natriuretic peptide in reproduction, pregnancy and fetal development. J Endocrinol 2004;180:17-22.
49. Del Ry S, Passino C, Maltinti M, Emdin M, Giannessi D. C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. Eur J Heart Fail 2005;7:1145-8.
50. Lisy O, Jougasaki M, Heublein DM, Schirger JA, Chen HH, Wennberg PW, et al. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int 1999;56:502-8.
51. Panteghini M, Clerico A. Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: the prerequisite for its optimal clinical use. Clin Lab 2004;50:325-31.
52. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000;46:529-34.
53. Clerico A, Prontera C, Emdin M, Passino C, Storti S, Poletti R, et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem 2005;51:445-7.
54. Emdin M, Clerico A, Clemenza F, Galvani M, Latini R, Masson S, et al. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J 2005;6:430-46.
55. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233-9.
56. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005;51:486-93.
57. van der Merwe DE, Henley R, Lane G, Field R, Frenneaux M, Dunstan F, et al. Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche Elecsys system. Clin Chem 2004;50:779-80.
58. Nowatzke WL, Cole TG. Stability of N-terminal pro-brain natriuretic peptide after storage frozen for one year and after multiple freeze-thaw cycles. Clin Chem 2003;49:1560-2.
59. Wu AH, Smith A, Wieczorek S, Mather JF, Duncan B, White CM, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628-31.
60. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004;6:355-8.
61. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006;52:1528-38.
62. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005;330:625.
63. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.
64. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.
65. Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998;135:21-8.
66. Ceriani L, Giovanella L. Cardiac natriuretic peptides after myocardial infarction: relationship with infarct size, left ventricular function and remodelling assessed by 99mTc-sestamibi gated-single photon emission tomography. Clin Chem Lab Med 2007;45:226-31.
67. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:372-80.
68. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004;110:3206-12.
69. Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C, et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005;112:1573-9.
70. Morello A, Lloyd-Jones DM, Chae CU, van Kimmenade RR, Chen AC, Baggish AL, et al. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J 2007;153:90-7.
71. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
72. Wieczorek SJ, Wu AH, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002;144:834-9.
73. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
74. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-74.
75. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-83.
76. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 2007;73:298-309.
77. Sharma R, Francis DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004;25:1021-8.
78. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006;27:1440-6.
79. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019-26.
80. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-7.
81. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
82. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-40.
83. Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol 2005;37:1938-47.
84. Lainscak M, von Haehling S, Anker SD. Novel biomarkers in heart failure: have we gone beyond BNP? Heart Fail Rev 2007; in press.
85. Anker SD, Coats AJ. Metabolic, functional, and haemodynamic staging for CHF? Lancet 1996;348:1530-1.
86. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-33.
87. Munzel T, Drexler H, Holtz J, Kurtz S, Just H. Mechanisms involved in the response to prolonged infusion of atrial natriuretic factor in patients with chronic heart failure. Circulation 1991;83:191-201.
88. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001;37:1820-6.
89. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci USA 2001;98:2703-6.
90. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
91. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91.
92. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. J Am Med Assoc 2005;293:1900-5.
93. Hauptman PJ, Schnitzler MA, Swindle J, Burroughs TE. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. J Am Med Assoc 2006;296:1877-84.
94. Wright SP, Prickett TC, Doughty RN, Frampton C, Gamble GD, Yandle TG, et al. Amino-terminal pro-C-type natriuretic peptide in heart failure. Hypertension 2004;43:94-100.
95. Igaki T, Itoh H, Suga S, Hama N, Ogawa Y, Komatsu Y, et al. C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney Int Suppl 1996;55:S144-7.
96. Barletta G, Lazzeri C, Vecchiarino S, Del Bene R, Messeri G, Dello Sbarba A, et al. Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans. Hypertension 1998;31:802-8.
97. Rutten JH, Korevaar JC, Boeschoten EW, Dekker FW, Krediet RT, Boomsma F, et al. B-type natriuretic peptide and amino-terminal atrial natriuretic peptide predict survival in peritoneal dialysis. Perit Dial Int 2006;26:598-602.
98. Austin WJ, Bhalla V, Hernandez-Arce I, Isakson SR, Beede J, Clopton P, et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006;126:506-12.
99. Mark PB, Stewart GA, Gansevoort RT, Petrie CJ, McDonagh TA, Dargie HJ, et al. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant 2006;21:402-10.
100. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997;336:828-34.
101. Kurnik BR, Weisberg LS, Askenase AD, Kurnik PB. Mannitol stimulates atrial natriuretic peptide release in humans. Am J Kidney Dis 1991;17:62-8.
102. Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon SH, et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 2006;243:16-22.
103. Hall KS, Wiklund T, Erikstein B, Holte H, Kvalheim G, Sommer HH, et al. Effects of dose-intensive chemotherapy and radiotherapy on serum N-terminal proatrial natriuretic peptide in high-risk breast cancer patients. Breast Cancer Res Treat 2001;67:235-44.